

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



創美·CH'MEI

CHARMACY PHARMACEUTICAL CO., LTD.

創美藥業股份有限公司

(A joint stock limited liability company established in the People's Republic of China)

(Stock Code: 2289)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of Charmacy Pharmaceutical Co., Ltd. (the “**Company**”) dated 11 April 2022 (the “**Announcement**”) in relation to, inter alia, the entering into the Framework Agreements. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as ascribed to them in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) further information on the Framework Agreements and the Annual Caps, (ii) the letter of advice from the independent financial adviser to the Independent Board Committee and the Independent Shareholders; (iii) the recommendation from the Independent Board Committee; and (iv) a notice of the EGM is expected to be despatched to the Shareholders on or before 4 May 2022.

As additional time is required for the Company to prepare and finalise certain information in the Circular, the despatch date of the Circular is expected to be postponed to a date on or before 31 May 2022.

By order of the Board
Charmacy Pharmaceutical Co., Ltd.
Yao Chuanglong
Chairman

Shantou, the PRC, 4 May 2022

As at the date of this notice, the executive Directors are Mr. Yao Chuanglong and Ms. Zheng Yuyan; the non-executive Director is Mr. Li Weisheng; and the independent non-executive Directors are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).